NLRP3 and systemic lupus erythematosus: Antagonists of TLR-7,−8, and−9 inhibit NLRP3 inflammasome-related pathways in NZBW F1 lupus model mice, and therefore represent a potential therapeutic approach for lupus treatment (66).